Hutchison China MediTech Limited (Chi-Med) has announced the first commercial launch of fruquintinib capsules (Elunate) ...
Shanghai Roche Pharmaceuticals Ltd. and Ascletis BioScience Co., Ltd. have jointly announced that starting from 1st Dec ...
Prenetics, a leading global genetic testing and digital health company announces the launch of Circle, a consumer DNA te...
The Hong Kong Polytechnic University (PolyU) and Alibaba Cloud, the cloud computing arm of Alibaba Group, have signed a ...
Mount Sinai Health System, New York’s largest integrated academic medical centre, has announced a historic agreeme...
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for bio...
HitGen Ltd has announced that the company has entered into a drug discovery research collaboration with Biogen to identi...
China Certification & Inspection Group (CCIC), a state-owned certification and inspection organization dedicated to ...
Alphamab Oncology has announced the successful completion of series A financing round, with more than $100 million raise...
MorphoSys AG and I-Mab Biopharma, a biotech company focusing exclusively on innovative biologics in immuno-oncology and ...
Gilead Sciences, Inc. has announced that the China National Medical Products Administration (NMPA) has approved Vemlidy ...
WuXi AppTec announces that its Laboratory Testing Division's new Medical Device Testing Center opens in Suzhou, Chi...
The Hong Kong Polytechnic University (PolyU) has reached strategic collaborative research framework agreements with Chin...
Chinese technology company YITU, which is dedicated to Artificial Intelligence (AI) research and innovation, has announc...
Angion Biomedica and Sinovant Sciences today announced a collaboration and license agreement for BB3, Angion’s inv...
F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumor...
Ascendis Pharma, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unm...
Japan's Eisai announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA&nbs...
